| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 22, 2007
Accepted on May 9, 2007
Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece (F.K.K., J.P.A.I.), Translational Research Center, Kyoto University Hospital, Kyoto University School of Medicine, Kyoto, Japan (T.A., H.H.), Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical University, Saitama, Japan (T.A., S.K., S.K.), Third Department of Internal Medicine Showa University School of Medicine, Tokyo, Japan (Y.B., Y.B.), Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (D.A.C.), Department of Hematology, Bone Marrow Transplantation and Blood Neoplastic Diseases, Medical Academy, Wroclaw, Poland (I.F.), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland (I.F., L.K., E.P.) Shiraz Institute for Cancer Research, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran (A.G.), Institute of Biomedical Research, Division of Medical Sciences, The Medical School, University of Birmingham, UK (S.C.G., J.M.H.), Department of Endocrinology, Kurume University School of Medicine, Kurume, Fukuoka, Japan (Y.H., I.M.), Human Molecular Genetics Laboratory of the Department of Forensic Medicine, Department of Diabetology, Newborn Pathology and Birth Defects and Department of Medical Genetics, Medical University of Warsaw, Poland (R.P., M.C.), Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan (P-W.W., R-T.L.), Department of Endocrinology, Medical Research Center, Polish Academy of Science, Warsaw, Poland, (T.B.), Department of Endocrinology, Medical University of Warsaw (T.B.), Department of Molecular Diagnostics, National Research Center GosNIIgenetika, Moscow, Russia (E.I.C.), Graduate Institute of Medical Genetics and Department of Clinical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan (H.H.J.), Endocrine and Metabolism Research Center, Namazee Hospital, Shiraz, Iran (G-H.R.O.), Division of Endocrinology and Metabolism, Showa University Fujigaoka Hospital, Yokohama, Kanagawa-ken, Japan (M.T.), Department of Medical Information, Showa University School of Pharmaceutical Science (T.T.), Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina, Greece (J.P.A.I.); Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, USA (J.P.A.I.)
* To whom correspondence should be addressed. E-mail: jioannid{at}cc.uoi.gr.
Context: CTLA-4 polymorphisms have been widely examined for their associations with autoimmune thyroid diseases (Graves' disease [GD] and Hashimoto thyroiditis [HT]) but their relative population effect remains unclear.
Objective: To generate large-scale evidence on whether the CTLA-4 polymorphisms (A49G and CT60) and haplotypes thereof increase the susceptibility to GD and/or HT.
Design, setting and participants Meta-analyses of group-level data from 32 (n=11019 subjects) and 12 (n=4479) published and unpublished studies for the association of the A49G polymorphism with GD and HT, respectively (Pubmed and HuGeNet search until 7/2006). Fifteen (n=7246) and 6 (n=3086) studies were available for the CT60 polymorphism, respectively. Meta-analyses of individual-level data from 10 (n=4906 subjects) and 5 (n= 2386) collaborating teams for GD and HT, respectively.
Main outcome measure: Association of gene variants and haplotypes with GD and HT.
Results: Group-level data suggested significant associations with GD and HT for both A49G (odds ratio 1.49, P=6x10-14 and 1.29 [P=0.001] per G allele, respectively) and CT60 (1.45, [P=2x10-9] and 1.64 [P=0.003] per G allele, respectively). Results were consistent between Asian and Caucasian descent subjects. Individual-level data showed that compared with the AA haplotype the risk conferred by the GG haplotype was 1.49 (95% CI: 1.31,1.70) and 1.36 (95% CI: 1.16,1.59) for GD and HT, respectively. Data were consistent with a dose-response effect for the G-allele of CT60.
Conclusions: The CT60 polymorphism of CTLA-4 maps an important genetic determinant for the risk of both GD and HT across diverse populations.
This article has been cited by other articles:
 |
|
 |
|
  A. Huber, F. Menconi, S. Corathers, E. M. Jacobson, and Y. Tomer Joint Genetic Susceptibility to Type 1 Diabetes and Autoimmune Thyroiditis: from Epidemiology to Mechanisms Endocr. Rev., October 1, 2008; 29(6): 697 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ban, D. A. Greenberg, T. F. Davies, E. Jacobson, E. Concepcion, and Y. Tomer 'Linkage Analysis of Thyroid Antibody Production: Evidence for Shared Susceptibility to Clinical Autoimmune Thyroid Disease J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3589 - 3596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hayashi, T. Kouki, N. Takasu, S. Sunagawa, and I. Komiya Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur. J. Endocrinol., June 1, 2008; 158(6): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Dideberg, G. Kristjansdottir, L. Milani, C. Libioulle, S. Sigurdsson, E. Louis, A.-C. Wiman, S. Vermeire, P. Rutgeerts, J. Belaiche, et al. An insertion deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases Hum. Mol. Genet., December 15, 2007; 16(24): 3008 - 3016. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
